We retrospectively analyzed the prognostic significance of mixed chimerism and associated clinical parameters in 80 patients following unmanipulated allogenic stem cell transplantation. Chimerism studies were performed on marrow aspirates using fluorescent in situ hybridization and variable number tandem repeats techniques at day þ 30, day þ 90 and þ 12 months. The median overall survival (OS) was 24 months (range, 1-56 months). Mixed chimerism was found in 23, 28 and 14% of patients at day þ 30 (1 month), þ 90 (3 months), and þ 12 months, respectively. Day þ 30 chimerism studies failed to provide any prognostic information. Day þ 90 mixed chimeras (MC) had significantly higher relapse rates compared to day þ 90 complete chimeras (CC) at 6 months (P ¼ 0.03) and 18 months when compared to MC (P ¼ 0.03) following transplant. The median OS in day þ 90 MC and day þ 90 CC were, respectively (95% CI, 2-35 months), compared to 47 months (95% CI, 20-74 months) (P ¼ 0.02). In conclusion, chimerism studies on day þ 30 could be reserved for patients who fail to demonstrate engraftment. Day þ 90 MC had higher relapse rates and lower OS, and therefore may be considered for novel therapies and future studies.
Introduction
Allogenic stem cell transplantation is performed with a curative intent in various malignant hematological disorders. Despite the use of various types of conditioning regimens, persistence of host hematopoietic cells (mixed chimerism) is frequently observed in the post-transplant period. Donor chimerism is an important tool for leukemia relapse and hematopoietic cell engraftment after allogeneic transplant. 1 In this molecular biology era, various techniques using polymerase chain reaction (PCR) or fluorescent in situ hybridization (FISH) can be used to assess the chimerism. These include Y PCR 2 in gender mismatch transplant and PCR of restriction fragment length polymorphisms or variable number tandem repeats (VNTR). 1, [3] [4] [5] Their sensitivity for detecting recipient cells has improved from 0.1 to 1%. Recently, a PCR technique that amplifies minisatellites has further enhanced the sensitivity from 0.01 to 0.1%. 6 Moreover, the optimal timing in the post-transplant period when chimerism has a predictive value has not been addressed in previous studies. Some investigators have reported a correlation between female gender, 7 lower age of the recipient 8 and less intensive conditioning regimen, 6, 7 with mixed chimerism. In the current retrospective study, we have addressed the potential prognostic significance of mixed chimerism in terms of relapse, disease-free survival (DFS) and overall survival (OS) at day þ 30, day þ 90 and at þ 12 months following a myeloablative unmanipulated allogenic stem cell transplantation, respectively.
Patients and methods

Patients
Allogenic stem cell transplantations were performed at Karmanos Cancer Institute, Wayne State University, Detroit, Michigan between 1995 and 1997. This time period was adequate to collect the samples needed to conduct this study. After informed consent and IRB approval was obtained, 80 patients were evaluated. The median age was 38 years (range, 2-63 years). The median follow-up was 24 months (range, 1-56 months). All patients were transplanted with unmanipulated bone marrow (n ¼ 73) or peripheral blood stem cells (PBSC) (n ¼ 7) either from an HLA-matched related donor (n ¼ 43) or HLA-matched unrelated donor (n ¼ 27) or HLA-mismatched (n ¼ 10) related donors. A conditioning regimen of total body irradiation (TBI) (total dose 1200 cGy) and chemotherapy was used in 22 patients and chemotherapy alone in 58 patients. Chemotherapy combination regimens used were busulfan, cytarabine and cyclophosphamide (n ¼ 38), busulfan and cyclophosphamide (n ¼ 19) and cyclophosphamide and cytarabine (n ¼ 1). Chemotherapeutic agents used with TBI were cyclophosphamide (n ¼ 9), melphalan (n ¼ 5) and etoposide (n ¼ 8). For prevention of graftversus-host disease (GVHD), patients received either cyclosporine (n ¼ 76) or tacrolimus (n ¼ 4) based on their preatory regimens; methotrexate or methylprednisolone was given as GVHD prophylaxis. Chimerism studies were performed on bone marrow aspirate samples at day þ 30, day þ 90 and þ 12 months using FISH or VNTR techniques (Table 1) .
Fluorescence in situ hybridization
FISH was carried out in all crossgender transplant patients. We assessed 500 interphase nuclei and five metaphase cells using CEP X spectrum orange/Y spectrum green DNA probes kit (Vysis Inc., Downers Grove, IL, USA, #30-161050). A cutoff point of 0.6% has been established for determining the presence of donor or recipient cells.
VNTR assay
Genomic DNA was extracted from recipient and donor peripheral blood mononuclear cells before ASCT and from bone marrow aspirate sample of recipient after ASCT by filter captures (Qiagen Inc., Valencia, CA, USA). The DNA was amplified using PCR and the resultant product was electrophoresed on 2% agarose gel containing ethidium bromide. 9 All samples were tested in duplicate. A negative (no DNA) control and a positive control containing known alleles were included in the assay. This method has a 5% detection limit of mixed cells by visual inspection of electrophoresed PCR product.
9,10
Definition of chimerism
Patients who showed no evidence of autologous cells in posttransplant period were considered complete chimeras (CC), whereas the patients who showed both recipient and donor cells were defined as mixed chimeras (MC). The sensitivity of detection of mixed chimerism was between 0.6% (by FISH) and 5% (by VNTR).
Statistical analysis
The relationship between clinical parameters and FISH or VNTR results that determined the chimerism status was tested using Mann-Whitney test. OS in two chimerism groups was estimated according to the Kaplan-Meier product limit method. The observed differences were assessed by the log-rank test. Correlation between FISH and VNTR results was tested using Pearson's correlation. Results were considered significant when the 'P'-value was o0.05. Data were analyzed using SPSS 10 software (Table 2) .
Results
In this single institution retrospective study, 80 patients were analyzed who underwent allogenic unmanipulated bone marrow or PBSC transplantation for various malignant disorders. Out of 80, 69 patients were evaluated and 11 patients were not evaluated secondary to withdrawing from evaluation prior to completion of the study. Of the 69 patients tested for day þ 30 chimerism status, 60/79 for day þ 90 and 21/62 for þ 12 months chimerism status. The median follow-up was 24 months (range, 1-56 months). In all, 27%(22/80) of patients relapsed at a median relapse interval of 9 months (range, 3-35 months). OS was 60% (48/80) at a median follow-up of 24 months (range, 1-56 months) following ASCT.
Kinetics of chimerism in first year post-transplant
The chimerism pattern was analyzed over a period of 1 year by serial monitoring at day þ 30, day þ 90 and þ 12 months following ASCT. Mixed chimerism was found in 23% (16/69) of patients at day þ 30, in 28% (17/60) at day þ 90 and in 14% (3/ 21) at þ 12 months. Patients considered as MC were always in remission by routine bone marrow examination. Both FISH and VNTR were carried out in 23 patients at day þ 30 and in 19 patients at day þ 90. A strong correlation was seen between FISH and VNTR results at day þ 30 (Po0.001) and day þ 90 (Po0.001). A comparison was made of the percentage of host cells detected in MC when tested simultaneously by FISH and VNTR. The chimerism pattern was not a static phenomenon. In all, 53% (28/53) of CC at day þ 30 and 31% (5/16) of MC at day þ 30 remained in the same chimerism status on follow-up testings, and thus the chimerism in these patients can be designated as stable chimerism. In 18 patients, chimerism pattern changed spontaneously and the following trends were observed.
MC converted to CC
A total of 55% (8/16) of MC at day þ 30 were spontaneously converted to CC by day þ 90. Two of these patients relapsed subsequently.
CC converted to MC
A total of 13% (7/53) of CC at day þ 30 were found to be MC at day þ 90 and two of these patients relapsed.
Transient mixed chimerism appearing in CC
A total of 6% (3/53) of CC at day þ 30 were converted to MC by day þ 90 and again reverted to complete chimerism on þ 12 months examination. One of these patients relapsed after reverting to complete chimerism. Since the time intervals for the chimerism tests were conducted between 2 and 9 months, other patients with these types of chimerism patterns might have gone undetected. Correlation between chimerism status at day þ 30 and clinical parameters
No significant association was found between chimerism status at day þ 30 and the age of the recipient, gender of the recipient and type of donor (HLA matched vs HLA-matched unrelated). Patients receiving HLA-matched related and HLA-unmatched related stem cells were pooled together for analysis as no difference was found in the incidence of mixed or complete chimerism when tested separately. Mixed chimerism was more frequent in conditioning regimens consisting of both TBI and chemotherapy and complete chimerism was more frequent in chemotherapy-only conditioning regimens (P ¼ 0.03). Acute and chronic GVHD were less frequent in MC when compared to CC, but the difference failed to reach statistical significance.
Chimerism analysis at day þ 90
We analyzed chimerism status at day þ 90 separately because it was not similar to day þ 30 chimerism status as explained under the kinetics of chimerism. Day þ 90 MC had significantly higher relapse rates when compared to day þ 90 CC at 6 months following transplant (23% (4/17) vs 7% (3/43) respectively, P ¼ 0.03) and also at 18 months (41% (7/17) vs 19% (8/43), respectively, P ¼ 0.03) following transplant (Figures 1 and 2) . Three other day þ 90 CC relapsed after 18 months, but none among day þ 90 MC. The difference in relapse rates among day þ 90 MC and day þ 90 CC after 18 months following transplant is not significant, maybe, due to a small number of events. The median relapse interval in day þ 90 MC was 6 months (range, 3-17 months), whereas in day þ 90 CC was 13 months (range, 3-28 months). DFS in day þ 90 MC and day þ 90 CC at 6 months following transplant was 69 vs 87%, respectively (P ¼ 0.03), and at 18 months following transplant it was 60 vs 85%, respectively (P ¼ 0.03). OS in day þ 90 MC (median, 19 months, 95% CI, 2-35 months) was significantly lower as compared to day þ 90 CC (median, 47 months, 95% CI, 20-74 months), P ¼ 0.02 ( Figure 3 ).
Correlation between chimerism status at day þ 90 and clinical parameters
No association was found between various clinical parameters and chimerism status at day þ 90. Chronic GVHD was more frequent in CC (63%) when compared to MC (41%), but failed to reach statistical significance.
Prognostic significance of chimerism status at þ 12 months
At þ 12 months, chimerism studies were performed only in 21 patients. A total of 14% (3/21) were found to be MC and 86% (18/21) were CC. The median OS for MC at þ 12 months was 14 months (95% CI, 2.8-25 months) and median OS for CC at þ 12 months has not been reached yet, P ¼ 0.04. In the present study, most of the relapses occurred at a median interval of 9 months, therefore þ 12 months chimerism status cannot be looked upon as a prognostic indicator of relapse. 
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Discussion
In the current retrospective study, we investigated the chimerism pattern of 80 patients following ASCT, its prognostic significance and factors affecting chimerism. Since chimerism testings were carried out at day þ 30, day þ 90 and þ 12 months, following the protocol scheduled marrows, an attempt was made to identify at each stage the prognostic significance of mixed chimerism in terms of relapse, DFS and OS. We found that chimerism in the post-transplant period is not a static phenomena. At day þ 30, mixed chimerism was found in 23% of the patients and in 28% when tested at day þ 90 following transplant. At þ 12 months, only 14% of the patients showed mixed chimerism. The incidence of mixed chimerism following unmanipulated marrow transplant has been reported between 11 and 57% 3, 6, [11] [12] [13] [14] and is much higher after T-celldepleted marrow grafts. 15, 14, [16] [17] [18] [19] In addition to stable mixed chimerisms and stable complete chimerisms, three other trends were observed in our study. A total of 55% (8/16) of MC at day þ 30 were converted spontaneously to CC by day þ 90. Similar trends have been reported by the study of Suttorp et al 20 , where 14% of patients were MC in the first 100 days and only 1% after 6 months. In the study of Bader et al, 13 3/12 MC converted to CC. A new phenomena observed in our study was that 6% (3/53) of CC at day þ 30 were found to be MC at day þ 90 and then again reverted to complete chimerism on þ 12 months examination. This type of intermittent mixed chimerism appearing in CC has not been described in the literature before and it is not related to relapse. Another feature that we observed was the spontaneous conversion of 13% (7/53) of CC at day þ 30 to MC by day þ 90. Two patients relapsed on follow-up in this group. Correlation of the above-mentioned changing chimerism patterns with relapse could not be ascertained due to a small number of patients in each of these groups.
In patients receiving unmodified marrow transplant for leukemias in early stage, relapse rates vary in different studies from 10 to 40%, depending on patient selection, treatment regimen and length of follow-up. [21] [22] [23] [24] In the present study, overall relapse rate was 27% (22/80) at a median relapse interval of 9 months (range, 3-35 months). Previous studies have yielded conflicting results with regard to influence of mixed chimerisms on relapse, DFS, and OS. [6] [7] [8] 11, 12, 15, 20, [25] [26] [27] [28] [29] . In our study, mixed chimerism at day þ 30 failed to predict relapse. One of the reasons for this may be that in the early post-transplant period, it has been observed that recipient T cells are often present that may contribute to mixed chimerism in total leukocyte samples without necessarily indicating imminent graft rejection. 30 MC at day þ 90 had significantly higher relapse rates as compared to day þ 90 CC at 6 months (23% (4/ 17) vs 7% (3/43), respectively, P ¼ 0.03) and at 18 months (41% (7/17) vs 19% (8/43), respectively, P ¼ 0.03) following transplant. Relapses seen in day þ 90 MC occurred within 18 months following transplant, but in day þ 90 CC late relapses were also seen. The correlation between the degree of mixed chimerism and relapse could not be analyzed due to the small number of MC. In other studies on patients with different hematological diseases, increasing levels of recipient cells (increasing mixed chimerism) over time following unmanipulated marrow or PBSC transplants appears to predict relapse. 6, 7, 15, 25 Bertheas et al 14 have reported that the probability of relapse was identical in patients with mixed chimerism and complete chimerism except in patients with chronic myeloid leukemia where mixed chimerism was significantly associated with increased risk of relapse. In the current study, OS in day þ 90 MC (median, 19 months, 95% CI, 2-35) was also significantly lower when compared to day þ 90 CC (median, 47 months, 95% CI, 20-74), P ¼ 0.02. Bader et al 25 also found significantly lower leukemiafree survival and OS in patients with increasing mixed chimerism when compared to CC. In another study, no significant difference of OS and leukemia-free survival was found between CC and MC. 7 No association was found between recipient age, recipient gender, type of donor (HLA matched vs unmatched) and mixed chimerism at day þ 30 or þ 90. Although at day þ 30, complete chimerism was more frequent with chemotherapyonly conditioning regimens and mixed chimerism with combination (TBI þ chemotherapy) regimens; these differences were not sustained in subsequent chimerism studies at day þ 90. Various other investigators have reported a relationship between TBI dose and mixed chimerism, 12, 31, 32 while others have found a relationship between the type of conditioning and the frequency of mixed chimerism. 33, 34 The differences in the incidence of acute and chronic GVHD among MC and CC at day þ 30 and þ 90 were not statistically significant. However, acute and chronic GVHD was seen in slightly higher number of day þ 30 CC than in MC. At day þ 90, the incidence of only chronic GVHD was higher among CC when compared to MC. All our patients received drug combination regimens, either cyclosporine or tacrolimus based as GVHD prophylaxis. Bader et al 25 also did not find any significant difference in the incidence of GVHD among MC and CC.
In conclusion, day þ 30 chimerism studies failed to provide any prognostic information in terms of relapse, DFS and OS, and thus could be reserved for patients who failed to demonstrate engraftment. MC at day þ 90 have significantly higher relapse and lower DFS and OS when compared to CC at day þ 90. Thus, in patients who are MCs at day þ 90, an attempt should be made to identify a subgroup likely to relapse by further analysis of chimerism within specific cell subsets by flow cytometry techniques or the employing other disease-specific markers such as fusion transcripts and clonality markers to confirm the origin and type of expanding recipient cells. Other risk factors such as disease status at the time of transplant, refractory disease and stage were not studied in this cohort of patients and must be taken into consideration with regard to overall survival. After carefully estimating risks and benefits in each of these patients, who are MCs at day þ 90, therapeutic interventions like modulation of immunosuppressive therapy or Kaplan-Meier estimate of survival in MC and CC at day þ 90 (P-value 0.02).
Significance of mixed hematopoietic chimerism R Lamba et al donor lymphocyte infusions might be considered as strategies to decrease the higher risk of relapse. Future prospective studies are needed to clearly define characteristics among MCs, which are predictive of disease relapse.
